Skip to main content
Future Journal of Pharmaceutical Sciences

Table 6 ANOVA for (a) drug release (Y1) and (b) disintegration time (Y2)

From: Optimized chronomodulated dual release bilayer tablets of fexofenadine and montelukast: quality by design, development, and in vitro evaluation

Source

Y 1

Y 2

Sum of squaresc

DFd

Mean squaree

F valuef

p value

Sum of squares

Degree of freedom

Mean square

F value

p value

Model

2469.82

3

823.27

37.28

< 0.0001*

15.16

3

5.05

684.94

< 0.0001*

A

1.53

1

1.53

0.0693

0.7983

0.0007

1

0.0007

0.0937

0.7665

B

2445.91

1

2445.91

110.77

< 0.0001*

15.10

1

15.10

2046.72

< 0.0001*

C

22.38

1

22.38

1.01

0.3404

0.0592

1

0.0592

8.02

0.0197*

Residuala

198.74

9

22.08

–

–

0.0664

9

0.0074

–

–

Cor Totalb

2668.55

12

–

–

–

15.22

12

–

–

–

Source

Y 1

     
 

Sum of square

Degree of freedom

Mean square

F value

p value

Model

285.03

3

95.01

27.54

< 0.0001*

A

0.0236

1

0.0236

0.0069

0.9358

B

275.59

1

275.59

79.88

< 0.0001*

C

9.42

1

9.42

2.73

0.1328

Residual

31.05

9

3.45

–

–

Cor Total

316.08

12

–

–

–

  1. *Significant (p < 0.05)
  2. aResidual sum of squares = observed value − predicted value
  3. bCor total: variation amount around observation mean
  4. cSum of squares: the sum of the squared difference between the overall average and the variation amount
  5. dDF (degrees of freedom): number of estimated parameters used to compute the sum of squares
  6. eMean square: sum of squares/DF
  7. fF value: test for comparing mean square to residual mean square
Back to article page